# Quethera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quethera

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.quethera.com
- Total disclosed funding: $0.6M
- Latest round: Seed (Aug 7, 2015)
- Investors on record: 4

## About

Quethera Limited focuses on developing innovative gene therapies specifically targeting glaucoma, leveraging advanced technology to improve patient outcomes through research and development.Quethera Limited, founded in 2013 and based in Cambridge, UK, specializes in gene therapy solutions for eye diseases. The company was acquired by Astellas Pharma Inc. in August 2018 for GBP 85 million. Quethera has completed a total of 3 deals since its inception. The founder's history remains unspecified.Quethera specializes in advanced technology solutions tailored for specific industry applications. Their core product offerings revolve around innovative software platforms designed to enhance operational efficiency and data management for businesses across various sectors. These solutions address critical pain points, such as data integration, analytics, and real-time reporting, enabling clients to make informed decisions and streamline workflows. Quethera's clientele includes mid to large-sized enterprises in the healthcare, finance, and logistics sectors, with a significant focus on markets in North America and Europe. By providing customizable solutions that cater to the unique needs of each customer, Quethera delivers substantial value, ultimately driving digital transformation within these industries.Quethera generates revenue primarily through a subscription-based model, allowing clients to access its software solutions with tiered pricing plans based on usage and features. This structure facilitates consistent cash flow and fosters long-term relationships with customers. Business transactions typically involve direct engagement with enterprises, where clients subscribe to specific service tiers that align with their operational requirements, often supplemented by added services such as consulting and support packages. The flagship offerings of Quethera’s product range are designed to promote seamless integration and efficiency, ultimately enhancing client retention and satisfaction. This strategic focus on subscription and service diversification positions Quethera to capitalize on ongoing market demand for robust technology solutions.Looking forward, in line with the August 2018 acquisition by Astellas Pharma, Quethera plans to accelerate research in innovative gene therapies for glaucoma, addressing unmet medical needs and improving patient outcomes. The funding will support these research initiatives as they aim to launch new products aimed at enhancing treatment options. Quethera is also targeting expansion into additional geographic markets, particularly in Europe and North America, to increase its reach and impact by 2024.

## Funding rounds

- Seed, Aug 7, 2015, $0.6M — Future Planet Capital Regional, Cambridge Enterprise, Parkwalk Advisors, UK Innovation Hub

## Investors

- Future Planet Capital Regional (https://capitalatlas.ai/funds/future-planet-capital-regional) — Seed
- Cambridge Enterprise — Seed
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Seed
- UK Innovation Hub (https://capitalatlas.ai/funds/uk-innovation-hub) — Seed